TheranosticTrials.org

Clinical Trial · NCT07118176

PET Imaging Study of 68Ga-FAPI-46 Biodistribution in cancer patients (FAPI Basket 3)

Overview

To define the biodistribution of 68Ga-FAPi-46 in normal and cancer tissues of patients with various malignancies measured by standardized uptake values (SUV). The goal is to determine where and to which degree 68Ga-FAPi-46 accumulates in normal and cancer tissues.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 1

Contacts

Andrew Nguyen (Staff Research Associate)

andtnguyen@mednet.ucla.edu

(310)-206-2466

Yuzin Arias Gonzalez (Clinical Research Coordinator)

yariasgonzalez@mednet.ucla.edu

(310) 206-7372

Lela Theus (Clinical Research Coordinator)

ltheus@mednet.ucla.edu

(310)-794-1589

ClinicalTrials.gov

NCT07118176

Drug / Compound

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules

Eligibility

Inclusion

  • • Patient is ≥ 18 years old at the time of the radiotracer administration.
  • • Patient can remain still for duration of imaging procedure (up to one hour)
  • • Patient can provide written informed consent.

Exclusion

  • • Patient is pregnant or nursing.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…